The Effect of Dapagliflozin on Platelet Function Testing Profiles in Diabetic Patients: The EDGE Pilot Study
| العنوان: | The Effect of Dapagliflozin on Platelet Function Testing Profiles in Diabetic Patients: The EDGE Pilot Study |
|---|---|
| المؤلفون: | Abhinav Karan, Stanley Giddings, Gabriella Grimaldos, Sangeeta Persad, Sadi Raza, Rajeev Seecheran, Antonio Tello-Montoliu, Aleena Ishmael, Darren Dookeeram, Kabeer Ali, Harun Abdullah, Srivane Richard, Naveen Seecheran, Lakshmipathi Peram, Kathryn Grimaldos, Shastri Motilal, David J. Schneider, Valmiki Seecheran, Ceylon Gomes |
| المصدر: | Cardiology and Therapy |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Aspirin, medicine.medical_specialty, business.industry, Urology, Dapagliflozin, Sodium-glucose co-transporter 2 inhibitor (SGLT2i), Clopidogrel, medicine.disease, Confidence interval, Coronary artery disease, chemistry.chemical_compound, Regimen, chemistry, Pharmacodynamics, VerifyNow™, medicine, Platelet function, Platelet reactivity, Cardiology and Cardiovascular Medicine, Adverse effect, business, Original Research, medicine.drug |
| الوصف: | Introduction This prospective pharmacodynamic (PD) study assessed the effect of the sodium-glucose co-transporter-2 inhibitor (SGLT2i), dapagliflozin, on platelet reactivity. Methods Patients with stable coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) (n = 27) who were on maintenance dual antiplatelet therapy (DAPT) of aspirin 81 mg daily, and clopidogrel 75 mg daily were recruited. Platelet function was evaluated with the VerifyNow™ P2Y12 assay (Werfen, Bedford, MA, USA) and assessed prior to initiation of and after 10 days of treatment with dapagliflozin 10 mg once-daily dose regimen. Results were compared with a paired t test. Results Treatment with dapagliflozin significantly decreased P2Y12 reaction units (PRU) by 20%, (95% confidence interval (CI) 8.5–32.6%, p value 0.002). The mean difference in PRU was 36.70 (95% CI 16.66–56.75). No patients experienced any serious adverse events (SAEs). Conclusions Significantly diminished platelet reactivity was observed on dapagliflozin as compared to without dapagliflozin. This dedicated pharmacodynamic study could be potentially informative and applicable for Trinidadian stable CAD patients with T2DM on DAPT. Further studies are required to confirm these exploratory findings. Clinical Trial Registration EDGE ClinicalTrials.gov number NCT04400760. |
| تدمد: | 2193-6544 2193-8261 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c03472f5a721588eaa446fb0f948b0f3Test https://doi.org/10.1007/s40119-021-00242-6Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....c03472f5a721588eaa446fb0f948b0f3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 21936544 21938261 |
|---|